Beclabuvir

Drug Profile

Beclabuvir

Alternative Names: BMS-791325

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Antivirals; Azabicyclo compounds; Benzazepines; Cyclohexanes; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Indoles; Organic bridged compounds; Phenyl ethers; Piperazines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Apr 2014 Bristol-Myers Squibb initiates enrolment in a phase I bioavailability trial in volunteers in United Kingdom (NCT02112110)
  • 22 Feb 2014 Discontinued - Phase-I for Hepatitis C in USA (PO) prior to 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top